Rothschild Investment LLC’s Matinas BioPharma MTNB Stock Holding History

Rothschild Investment LLC’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9	Hold	14	–	–	﹤0.01%	3621
2026 Q1	$7	Hold	14	–	–	﹤0.01%	3586
2025 Q4	$8	Hold	14	–	–	﹤0.01%	3385
2025 Q3	$26	Hold	14	–	–	﹤0.01%	3112
2025 Q2	$12	Hold	14	–	–	﹤0.01%	3008
2025 Q1	$7	Hold	14	–	–	﹤0.01%	3018
2024 Q4	$7	Hold	14	–	–	﹤0.01%	2944
2024 Q3	$50	Buy	14 +1	+8%	+$6	﹤0.01%	2873
2024 Q2	$104	Hold	13	–	–	﹤0.01%	2732
2024 Q1	$179	Hold	13	–	–	﹤0.01%	1798
2023 Q4	$143	Buy	+13	New	+$147	﹤0.01%	1287

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Rothschild Investment LLC's MTNB Position: Q2 2026 in Review

Rothschild Investment LLC held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 14 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Rothschild Investment LLC first reported a position in MTNB in Q4 2023 and has held it in 11 quarters since. The position peaked at $179 in Q1 2024. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Rothschild Investment LLC held 14 shares of Matinas BioPharma worth $9 as of Q2 2026.
Rothschild Investment LLC left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3621 holding.
Rothschild Investment LLC first reported a position in Matinas BioPharma in Q4 2023 and has held it in 11 quarters since.
Rothschild Investment LLC's Matinas BioPharma position peaked at $179 in Q1 2024.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.